Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 201...
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: GlobeNewswire
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker activity supports clinical impact of SD-101’s activity- - Conference call and webcast to review all Dynavax data presented at the ESMO 2018 Congress on Sunday, October 21st at 1:00 PM EDT- BERKELEY, Calif., Oct. 20, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today presented interim data from its ongoing Phase 1b/2 SYNERGY-001 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada) in patients with advanced melanoma naïve to anti-PD-1/L1 therapy. These data were presented in a late breaking poster and discussion session today at the ESMO 2018 Congress, in Munich, Germany. The company reported results on a total
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- Dynavax Technologies Co. (NASDAQ: DVAX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024PR Newswire
- Dynavax Technologies Co. (NASDAQ: DVAX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Global Human Vaccines Market (2023-2028) [Yahoo! Finance]Yahoo! Finance
- Those who invested in Dynavax Technologies (NASDAQ:DVAX) five years ago are up 68% [Yahoo! Finance]Yahoo! Finance
DVAX
Earnings
- 2/22/24 - Beat
DVAX
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- DVAX's page on the SEC website